Compare Incyte Corporation (INCY) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Newegg Commerce Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Newegg Commerce Inc trades at $11.58 (market cap $243.30M). The key difference: Incyte Corporation is far larger — about 93.9× Newegg Commerce Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Newegg Commerce Inc for 14 Days on average.
| INCY | NEGG | |
|---|---|---|
Market Cap | $22.85B | $243.30M |
Volume | 1,927,029 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $92.74 |
52-Week Low | $83.80 | $11.49 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $18.35B | $213.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
NEGG trades at $11.58, down 3.58% today, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 projections. Recent partnerships with Western Digital and HPE highlight strategic moves in AI and enterprise IT markets, while insider selling has created near-term pressure.
The stock presents a mixed picture with improving profitability but significant execution risks. While analyst consensus remains bullish with 100% buy ratings, the $7.75 price target suggests 33% downside from current levels. Key risks include volatile cash flows, competitive e-commerce pressures, and the need to sustain recent margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
